Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SOLX is a proprietary red blood cell (RBC) additive solution developed by Haemonetics Corporation, specifically designed for use with the LeukoSep Leukocyte Reduction Filtration System. It serves as a preservative medium that extends the shelf life of red blood cells to 42 days by providing essential metabolic substrates and maintaining physiological conditions during refrigerated storage. The solution typically contains a combination of nutrients and buffers, such as adenine, dextrose, and phosphate, which help maintain cellular ATP levels and 2,3-diphosphoglycerate (2,3-DPG) concentrations, thereby preserving the oxygen-carrying capacity and viability of the RBCs for transfusion. SOLX is used following the collection of whole blood in an anticoagulant like CPD (Citrate Phosphate Dextrose) and is intended for patients requiring blood transfusions due to anemia or acute blood loss.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SOLX (Haemonetics).